Contineum CEO sells 2,500 shares after option exercise

Rhea-AI Filing Summary

Contineum Therapeutics, Inc. (CTNM) reported that CEO and President Carmine N. Stengone exercised options to acquire 2,500 shares of Class A common stock on September 8, 2026 at an exercise price of $1.01 per share and sold 2,500 shares on the same day at a weighted average price of $16.4566 per share. The option was granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, is fully vested, and after this exercise 274,430 option shares from this award remain outstanding. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on September 23, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,500 shares ($39K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Stengone Carmine N.

Role CEO and President

Sold 2,500 shs ($41K)

Approx. gross sale proceeds $41K

Approx. exercise cost $3K

Approx. pre-tax spread $39K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F3	2,500	$0.00	$0.00
Exercise	Class A Common Stock F1	2,500	$1.01	$3K
Sale	Class A Common Stock F1, F2	2,500	$16.4566	$41K

Holdings After Transaction: Stock Option (right to buy) — 274,430 contracts (Direct); Class A Common Stock — 17,217 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
3. F3. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Key Figures

Options exercised: 2,500 shares Option exercise price: $1.01 per share Shares sold: 2,500 shares +5 more

8 metrics

Options exercised 2,500 shares Class A common stock acquired by option exercise on September 8, 2026

Option exercise price $1.01 per share Exercise price for the 2,500 shares on September 8, 2026

Shares sold 2,500 shares Class A common stock sold on September 8, 2026

Weighted average sale price $16.4566 per share Average for sales ranging from $16.29 to $16.59 on September 8, 2026

Sale price range $16.29–$16.59 per share Price range for the 2,500 shares sold on September 8, 2026

Remaining option shares from this award 274,430 shares Options to buy Class A common stock remaining after exercise; option expires February 24, 2030

Option expiration date February 24, 2030 Expiration of the option award under the 2012 Equity Incentive Plan

Rule 10b5-1 plan adoption date September 23, 2025 Date the trading plan governing these transactions was adopted

Key Terms

Rule 10b5-1 trading plan, weighted average price, Equity Incentive Plan

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Equity Incentive Plan financial

"Options granted under the Issuer's 2012 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CTNM’s CEO report on September 8, 2026?

Carmine N. Stengone reported exercising options for 2,500 shares of Class A common stock at $1.01 per share and selling 2,500 shares at a weighted average price of $16.4566 per share on September 8, 2026.

At what prices were the CTNM shares sold in the September 8, 2026 transaction?

The filing reports a weighted average sale price of $16.4566 per share. The 2,500 shares were sold in multiple trades at prices ranging from $16.29 to $16.59 per share, inclusive.

What was the exercise price of the CTNM stock options used in this Form 4?

The options were exercised to acquire 2,500 shares of Class A common stock at an exercise price of $1.01 per share. These options were granted under Contineum Therapeutics’ 2012 Equity Incentive Plan and are fully vested.

How many CTNM option shares from this grant remain after the reported exercise?

After exercising options for 2,500 shares, the reporting person shows 274,430 option shares from this award remaining outstanding, with an expiration date of February 24, 2030.

Were the CTNM insider transactions made under a Rule 10b5-1 trading plan?

Yes. The filing states that these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

What equity plan covers the options exercised in this CTNM Form 4?

The options exercised for 2,500 shares of Class A common stock were granted under Contineum Therapeutics’ 2012 Equity Incentive Plan, and the filing notes that the option is fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 06:09 PM EDT Accepted by SEC EDGAR 09/08/2026 - 06:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stengone Carmine N.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/08/2026		M(1)		2,500	A	$1.01	19,717	D
Class A Common Stock	09/08/2026		S(1)		2,500	D	$16.4566(2)	17,217	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.01	09/08/2026		M(1)			2,500	(3)	02/24/2030	Class A Common Stock	2,500	$0	274,430	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.

Remarks:

	/s/ Peter Slover, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)